SGN-2FF

• Description :

  SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H320

• Target :

  Glycosyltransferase

• Type :

  Reference compound

• Related Pathways :

  Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/SGN-2FF.html

• Purity :

  98.0

• Solubility :

  DMSO : 50 mg/mL (ultrasonic) |H2O : 36.67 mg/mL (ultrasonic)

• Smiles :

  F[C@H]1[C@@H]([C@@H]([C@H](C)OC1O)O)O

• Molecular Formula :

  C6H11FO4

• Molecular Weight :

  166.15

• Precautions :

  H315, H319, H320

• References & Citations :

  [1]Stephen C. Alley, et al. Abstract DDT02-02: SGN-2FF: A novel small molecule inhibitor of fucosylation with preclinical antitumor activity through multiple immune mechanisms. Cancer Res 2017;77 (13 Suppl) .

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [2089647-47-0]